tooltip
{{SelectedCountryName}}
  • {{country.Country1}}
{{SelectedStateName}}
  • {{state.State1}}
{{SelectedCountyName}}
  • {{county.CountyName}}
{{SelectedCityName}}
  • {{city.City}}
  Lock Location
Blogs
  • Home
  • Businesses
  • Stores
  • Products
  • Board
  • People Board
  • People
  • Networks
  • Groups
  • Videos
  • Images
  • Blogs
  • Classifieds
  • Audios
  • Maps
  • Channels
  • Deals
  • Coupons
Flip   +  Add

Business Blogs

Blogs
  • Board
  • Stores
  • Businesses
  • People
  • Products
  • Videos
  • Images
  • Blogs
  • Audios
  • Coupons
  • Deals
  • Classifieds
  • Networks
  • Groups
  • Forums
  • Maps

    The Boeing Company (BA) Multibillion-Dollar Order Continues 737 MAX 8 Momentum

    Karl Stemtrowsky
    Posted By:
    Location:
    Storeboard City:
    Status: Pharmacyclics Inc. (PCYC) reported trial results of the first Phase III study (RESONATE, PCYC-1112-CA), a head-to-head comparison of IMBRUVICA(R) (ibrutinib) versus ofatumumab in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (a slow-growing lymphoma in which too many immature white blood cells cause lymph nodes to become larger than normal).According to PCYC, patients receiving IMBRUVICA realized a significant improvement in progression free survival, overall survival and overall response rate as compared to patients receiving ofatumumab. http://finance.crwe-pr.com/2014/06/01/trials-positive-data-advaxis-nasdaqadxs-cervical-cancer-abbvie-nyseabbv-and-pharmacyclics-nasdaqpcyc-chronic-lymphoma-leukemia/
    Spacer
    3,403 Days Ago